Tracer library / [90Y]Y-Daclizumab

[90Y]Y-Daclizumab

Also written as [90Y]Y-Daclizumab
Radionuclide
Y-90
Modality
—
Production route
—
Stage
Clinical research
Syntheses indexed
0
Lymphoma

What it is

Compound class
Monoclonal antibody (anti-CD25)
Target / mechanism
CD25 (IL-2 receptor alpha subunit) PMID 26438866
Clinical application
Refractory and relapsed Hodgkin's lymphoma PMID 26438866
Theranostic pair
—

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

  1. 90Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma.
    2020 · Cancer Biother Radiopharm · Clinical study
  2. 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.
    2015 · Proc Natl Acad Sci U S A · Clinical study

Need this precursor?We can point you to suppliers for [90Y]Y-Daclizumab, or handle the enquiry for you.

Get in touch

Notes

Added at stage 39 (2026-09-27) from a reverse search of the PubMed corpus's own unattached articles (articles that named a real compound not yet in this reference): 2 article(s) found under this name, not yet individually researched. Target/mechanism, clinical application, indications, approval, modality, stage and production route are intentionally left empty. PMIDs: 26438866, 32275165. Stage set/updated at stage 39 from PMID 32275165: 'This was a single institution, nonrandomized, open-label phase I/II trial of radiolabeled 90Y-daclizumab, an anti-CD25 monoclonal antibody, BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning treatment followed by autologous hematopoietic stem cell transplant (ASCT).'.